Helen Tuvesson - Active Biotech Chief Scientific Officer
| ACTI Stock | SEK 0.27 0.02 8.00% |
Executive
Ms. Helen Tuvesson was appointed President and Chief Executive Officer at Active Biotech AB effective as of July 1, 2017. She has previously served as Chief Scientific Officer at Active Biotech AB since April 1, 2011. She was previously Head of Preclinical Development at the Company until April 1, 2011 since 2017.
| Age | 61 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 46 46 19 20 00 |
| Web | https://www.activebiotech.com |
Active Biotech Management Efficiency
The company has return on total asset (ROA) of (0.6714) % which means that it has lost $0.6714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4389) %, meaning that it generated substantial loss on money invested by shareholders. Active Biotech's management efficiency ratios could be used to measure how well Active Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | EXECUTIVE Age | ||
| Lena Wange | Orexo AB | N/A | |
| Steve Kim | Anoto Group AB | 55 | |
| Andres McAllister | BioInvent International AB | 67 | |
| Jesper Lind | Orexo AB | 63 | |
Management Performance
| Return On Equity | -1.44 | |||
| Return On Asset | -0.67 |
Active Biotech AB Management Team
Elected by the shareholders, the Active Biotech's board of directors comprises two types of representatives: Active Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Active. The board's role is to monitor Active Biotech's management team and ensure that shareholders' interests are well served. Active Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Active Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Helen Tuvesson, Chief Scientific Officer | ||
| Hans Kolam, Chief Officer | ||
| Erik Vahtola, Chief Officer |
Active Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Active Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 224.92 M | |||
| Shares Outstanding | 264.89 M | |||
| Shares Owned By Insiders | 45.94 % | |||
| Shares Owned By Institutions | 15.84 % | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 5.63 X | |||
| Price To Sales | 29.72 X | |||
| Gross Profit | 6.72 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Active Stock Analysis
When running Active Biotech's price analysis, check to measure Active Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Active Biotech is operating at the current time. Most of Active Biotech's value examination focuses on studying past and present price action to predict the probability of Active Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Active Biotech's price. Additionally, you may evaluate how the addition of Active Biotech to your portfolios can decrease your overall portfolio volatility.